Genmab A/S
GNMSF
$274.75
$9.913.74%
OTC PK
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 26.33% | 24.87% | 28.98% | 34.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 26.33% | 24.87% | 28.98% | 34.80% |
| Cost of Revenue | -- | 126.93% | 164.89% | 173.05% | 352.11% |
| Gross Profit | -- | 23.14% | 21.56% | 25.58% | 30.39% |
| SG&A Expenses | -- | 15.41% | 10.80% | 14.31% | 20.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 20.98% | 22.05% | 26.79% | 35.19% |
| Operating Income | -- | 37.83% | 30.85% | 33.63% | 33.98% |
| Income Before Tax | -- | 35.08% | 27.84% | 31.63% | 66.01% |
| Income Tax Expenses | -- | -37.83% | -21.60% | -17.04% | 8.93% |
| Earnings from Continuing Operations | -- | 61.17% | 42.50% | 46.06% | 82.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 61.17% | 42.50% | 46.06% | 82.85% |
| EBIT | -- | 37.83% | 30.85% | 33.63% | 33.98% |
| EBITDA | -- | 37.28% | 31.39% | 33.31% | 33.74% |
| EPS Basic | -- | 66.02% | 45.79% | 49.45% | 86.85% |
| Normalized Basic EPS | -- | 32.00% | 38.25% | 30.51% | 57.23% |
| EPS Diluted | -- | 66.18% | 45.95% | 49.55% | 86.95% |
| Normalized Diluted EPS | -- | 32.16% | 38.45% | 30.64% | 57.34% |
| Average Basic Shares Outstanding | -- | -2.86% | -2.13% | -2.13% | -1.91% |
| Average Diluted Shares Outstanding | -- | -3.06% | -2.36% | -2.33% | -2.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |